Partnership15 Apr 2026, 04:01 pm
Aurobindo Pharma's TheraNym expands CMO deal with MSD, invests $150-175M
AI Summary
Aurobindo Pharma's subsidiary, TheraNym Biologics Private Limited, has expanded its existing Contract Manufacturing Organization (CMO) agreement with Merck Sharp & Dohme Singapore Trading Pte Ltd (MSD) by executing an additional product schedule. This expansion will involve TheraNym constructing a greenfield large-scale mammalian Drug Substance manufacturing facility ("Unit 2") with a total of 60 KL bioreactor capacities. TheraNym will invest approximately USD 150 to 175 million for this facility, which will also include requisite downstream purification infrastructure. This move further strengthens the CMO relationship initiated in May 2024, with TheraNym building, manufacturing, and supplying products to MSD.
Key Highlights
- TheraNym expands CMO agreement with MSD via new product schedule.
- Subsidiary to build 60 KL mammalian Drug Substance facility (Unit 2).
- Investment of USD 150-175 million for the new manufacturing unit.
- Further strengthens existing contract manufacturing relationship.